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Abstract
Research in the emergency setting involving patients with acute clinical conditions is needed if 
there are to be advances in diagnosis and treatment. But research in these areas poses ethical and 
practical challenges. One of these is the general inability to obtain informed consent due to the 
patient’s lack of mental capacity and insufficient time to contact legal representatives. Regulatory 
frameworks which allow this research to proceed with a consent ‘waiver’, provided patients lack 
mental capacity, miss important ethical subtleties. One of these is the varying nature of mental 
capacity among emergency medicine patients. Not only is their capacity variable and often 
unclear, but some patients are also likely to be able to engage with the researcher and the context 
to varying degrees. In this paper we describe the key elements of a novel enrolment process for 
emergency medicine research that refines the consent waiver and fully engages with the ethical 
rationale for consent and, in this context, its waiver. The process is verbal but independently 
documented during the ‘emergent’ stages of the research. It provides appropriate engagement with 
the patient, is context-sensitive and better addresses ethical subtleties. In line with regulation, full 
written consent for on-going participation in the research is obtained once the emergency is 
passed.
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Introduction
Research in the emergency setting involving patients with acute clinical conditions 
(including acute myocardial infarction (AMI) and stroke) is needed if there are to be 
advances in the diagnosis and treatments of those conditions. Despite its importance, 
research in these areas poses several ethical and practical challenges, not least in the area of 
patient consent. Fully informed consent, a central pillar of research ethics, cannot, for the 
most part, be obtained where the patient is in severe pain, incapacitated or under influence of 
powerful analgesic or sedative medication and where treatments need to be given very 
rapidly.
Regulatory frameworks have been developed to allow this research to proceed with a 
consent waiver but these frameworks miss important ethical subtleties. The process of 
enrolment described below applies to research involving patients who may be unable to 
provide written, fully informed consent because of an acute clinical condition and for whom 
there is no time to contact an approved representative. It represents a significant refinement 
of the simple consent waiver because it captures important ethical nuances without 
jeopardising the conduct of research.
Emergency Medicine Research
Well-known clinical trials such as ISIS (1, 2, 3), TROICA (4), CRASH (5,6), PAD (7) and 
PolyHeme (8) have all contributed significantly to acute patient care but they have also 
raised the profile of the ethical issues. Including UK patients in the international TROICA 
trial was initially prohibited by the UK Medicines for Human Use Act as this did not permit 
consent waivers. TROICA prompted an amendment to the Act (9, 10). In the US a range of 
trials and the generally recognised need to conduct research on resuscitation led to the 
production of the US Federal Regulations on the exception from informed consent in 
emergency research (11, 12).
There is a definite and continued need for research studies and clinical trials involving 
patients who are in the most acute clinical conditions in the emergency setting. For example, 
thrombolysis and emergency percutaneous coronary intervention (PCI) have yielded major 
benefits for patients compared with the pre-thrombolytic era. Further advances in the 
management of AMI require new experimental medicine studies and clinical trials, which 
are likely to be conducted within the context of immediate diagnosis and treatment by 
emergency PCI.
Ethics and regulation
There are two conventional principles of research ethics that conflict in the emergency 
medicine research context. First, it is ethically important that research in emergency 
medicine should proceed. As outlined above, without the knowledge that such research 
generates, emergency medicine clinicians are unable to discharge their obligations to 
continue to increase benefit and reduce potential harm to their patients. Second, it is usually 
considered imperative that participants give fully informed consent to be enrolled in the 
study (13, 14, 15).
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Regulatory systems across the globe recognise that often both of these requirements cannot 
be satisfied in the emergency context. Patients require treatment urgently so there is little 
time for explanation, discussion and reflection. Patients may also be in extreme pain or 
shock, suffering from hemodynamic compromise, have already received opiates or be 
terrified thus compromising their capacity to make a considered decision. Both time and 
capacity are required for fully informed consent (16, 17). As a result the regulatory systems 
generally grant, under certain conditions (see Figure 1), an exemption from the requirement 
to obtain informed consent. Most importantly this exemption is based on the idea that 
informed consent requires capacity and that capacity will be lacking in many of the potential 
subjects of this research.
The new EU Clinical Trials Regulations No 536/2014 (18) with application from May 2016 
accepts a “derogation” from written informed consent in certain emergency situations where 
it is not possible to obtain informed consent prior to an individual’s participation in a trial. In 
the UK the Medicines for Human Use (Clinical Trials) Amendment (No.2) (19) and the 
Mental Capacity Act (20) both allow research to be conducted on patients who lack capacity, 
with a ‘waiver’ of consent. In the US, the Federal Regulations allow an exception from the 
requirement to obtain informed consent (12, 21). In both cases, the authority to approve the 
use of the waiver is granted to Research Ethics Committees (RECs) subject to certain 
constraints (see Figure 1). More broadly, both the International Council for Harmonisation 
Good Clinical Practice Guidelines (ICH-GCP) and the Council for International 
Organizations of Medical Sciences (CIOMS) explicitly permit research on patients with 
acute clinical conditions subject to conditions very similar to those in place in the UK and 
the US (14, 15).
The problem
Research in the emergency context may need to be conducted even when the potential 
subject is incapable of giving their consent. For patients who are unconscious and when the 
relevant regulatory conditions (see Figure 1) are met, the requirement to obtain informed 
consent for these interventions can be waived. There will however be a group of patients 
who are conscious but will clearly lack capacity; others will remain on the edge of capacity; 
while still others will maintain the ability to make decisions. In ethical and legal terms, for 
this group of patients, the important issue is capacity: if the conscious patient has the 
capacity to decide, the regulations (and hence the consent waiver) do not apply. Not only is 
the capacity of patients in this group variable and often unclear, but because they are 
conscious they are also likely to be able to engage with the researcher and the context to 
varying degrees.
One option is to formally assess the capacity of potential research participants. This faces 
several serious difficulties. First, there are practical difficulties with requiring a suitably 
qualified individual always to be available for the formal determination of capacity. Second, 
such an assessment would take time where little or none may be available. Third, requiring a 
determination of capacity presumes that capacity is a binary concept. Capacity is usually 
taken to involve the ability to comprehend, retain and use information in making a decision 
(22). But clearly each person’s ability to satisfy these conditions will vary with context and 
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content and hence, that capacity will be a matter of degree (23). In considering issues of 
research ethics, there is a mismatch between the binary operation of the consent waiver and 
the extent to which individuals are able to comprehend what is happening to them. The 
problem here is that an individual may fail the ‘capacity test’ and yet be conscious enough to 
know that something different is happening about which they have not been informed, and / 
or to which they may not agree. By insisting on a strict determination of capacity this 
approach fails to take into account the realities of the situation and the nuances of the ethical 
relationships within them.
Refining the process
In what follows below we describe the key elements of an enrolment process for emergency 
medicine research that refines the consent waiver and addresses the challenges outlined 
above. These elements serve as an explanation of the flowchart of the process depicted in 
Figure 2. The key points of the process are summarised in text format (Figure 3).
1 Verbal consent
Overall, the emergency context provides a good justification for a consent process which is 
primarily verbal. As Roberts et al suggest there is evidence to suggest that requiring a 
detailed, written consent process in this context is potentially detrimental to the patient’s 
health (17, 24).
What matters ethically for consent is that the autonomous (and so competent) person makes 
a voluntary decision having been given (and understanding) the relevant information. 
Importantly, there is nothing in this that requires consent to be written. It is an artefact of 
regulation and the need for evidence in this context. In the emergency context there is good 
reason to avoid unnecessary steps. However, it remains important, for the same reason that 
regulation is important, to have a record of the process that is independent of the researcher 
(25). Instead of requiring written consent, a verbal1 but independently documented process 
is one that is sensitive to the context of the research and the ethical issues surrounding 
consent.
2 Unconscious patients are enrolled on the consent waiver; Conscious patients go 
through a consent/assent process
The important ethical feature of the group of patients who are conscious but with unclear 
capacity is that they can, to varying degrees, engage with the researcher. There is a clear 
obligation on the part of both clinicians and researchers to engage with those patients who 
can, to the extent that the patient is able. The UK Mental Capacity Act acknowledges this 
obligation: “Nothing may be done to, or in relation to, [the patient] in the course of the 
research to which he appears to object (whether by showing signs of resistance or otherwise) 
except where what is being done is intended to protect him from harm or to reduce or 
prevent pain or discomfort” (26).
1A verbal process does not exclude non-verbal communication (gestures, expressions, head movements) which could also indicate 
consent or assent to study inclusion.
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As a result, the process requires that the researcher responsible for the patient explains 
briefly and alongside whatever account of the clinical process is usually given, that research 
is being conducted and that they are eligible for enrolment. The study will, as far as possible, 
be discussed with the patient and the risks and benefits explained. Patients will be given the 
option to participate or not. In cases where capacity is unclear, any sign (verbal or non 
verbal) either to enrol in the study or not will be registered as assent or dissent. In cases of 
dissent the patient will not be entered into the study. This explanation and patients’ 
responses do not stand in for a full consent process. It is verbal and truncated because of the 
emergency and it is delivered to all conscious patients to enable appropriate engagement. 
Those with capacity will understand and be able to consent in a truncated form while those 
with limited capacity will be given an opportunity to assent to (or dissent from) participation 
and so will be involved in the process to an appropriate extent. Judgement is required here to 
interpret any response on the part of the patient particularly in the negative. So while 
conscious patients are unlikely to be able to give full consent on this process they are given 
the opportunity to participate in the decision-making to the extent that they are able.
3 Patient Advocate
The Patient Advocate (PA) role is filled by a heath care professional present in the 
emergency room but independent of the research team, e.g. a clinical nurse or radiographer. 
The PA plays two important roles in the process: (i) to be an independent witness and to 
document that the process was undertaken appropriately and (ii) to provide an independent 
assessment of the patient’s willingness or otherwise to participate in the research. The latter 
role requires the PA to witness the exchange between the researcher and the patient about the 
research study and to make a judgement in conjunction with the researcher about any 
affirmative or negative response by the patient. The patient advocate is not a surrogate for 
the patient or the legal representative of the patient but a trained independent observer who 
oversees the consent process and is in a position to interpret the patient’s condition and 
responses to the researcher.
4 Consent for on-going participation
In line with regulatory requirements, full written consent for on-going participation in the 
research is obtained from the patient or their representative once the emergency is passed.
Conclusions
The process that we have outlined represents a nuanced approach to the research ethics 
around consent in the challenging context of emergency medicine research. The process 
suggested here does not involve a detailed, burdensome and time-consuming exercise that is 
often true of informed consent processes.
It balances the pressing need to conduct research in the emergency setting with an ethical 
approach that strives to inform and consult patients before their participation. It does not 
require simply withholding relevant information about research from participants and it does 
not require delays in life-saving interventions. Instead it is firmly embedded within the 
context of the consent waiver but represents an appropriate refinement of the regulations that 
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is better able to capture the ethical complexity of the context. It is context and patient 
sensitive. Most importantly, it is centred on a recognition that treating people well involves 
treating them honestly and engaging with them at a level appropriate to their specific 
circumstances.
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Figure 1. Shared requirements for a consent waiver.
The requirements listed are common to regulators from UK, EU and US
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Figure 2. Refined enrolment process in emergency medicine research
Emergency admission patients eligible for inclusion in research follow one of three routes. 
An independent advocate oversees the process. Written consent is sought after the 
emergency is passed.
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Figure 3. Key Elements of the new process
Key elements are described below
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